medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2006, Number 2

<< Back Next >>

Arch Med Fam 2006; 8 (2)

Criteria for Prescribing Hypolipemiant Treatment in a Mexico City-based Family Medicine Unit

Palestina-Antunes MI, Ocampo-Barrio P, Quiroz-Pérez JR

Language: Spanish
References: 13
Page: 103-108
PDF size: 85.10 Kb.


ABSTRACT

Objective: Our aim was to determine and compare criteria used by the Family Physician for prescribing hypolipemiant treatment. Materials and Methods: We conducted an observational, transversal, and comparative study among Family Medicine Specialists and General Physicians affiliated with a primary-level healthcare unit. For information collecction, we constructed and validated an instrument ex profeso, and employed descriptive and inferential statistics for study results analysis. Results: The study sample was made up of 50 physicians (60%, Family Medicine Specialists and 40%, General Physicians). Eighty two percent of physicians used the following criteria for pharmacologic prescription: 12%, exclusively quantitative criteria, and 6%, qualitative criteria. There were no statistically significant differences between Specialists and non-Specialists, and years of seniority as a medical professional appeared not to possess an influence. Conclusions: Experience obtained during the development of professional activities and academic formation did not appear to exert an influence on the criteria utilized for prescribing hypolipemiant pharmaceuticals, perhaps as a result of the organizational and work systems of the Health Institutions involved.


REFERENCES

  1. González TG, Guevara RM. Dislipidemias, actualidad y perspectivas. http://www.iladiba.com/upr/1998/No121998/HTM/dislip1.asp.

  2. Escuela chilena de medicina http://www.med.uchile.cl/apuntes/archivos/2004/medicina/dislipidemias2.pdf.

  3. Vargas M, Vargas U. Valores de referencia para el perfil lipídico. Laboratorio de Bioquímica, INCIENSA y Departamento de análisis clínicos, Facultad de Microbiología. Disponible en UCR http://cariari.ucr.ac.cr/-gacetapc/LIPIDOS.HTM.

  4. Carey CH, Lee HF, Woeltje K. Manual Washington de terapéutica médica. 10a Masson serie manuales. México, 1999: 503-12.

  5. Aguilar CA, Rojas MC, Gómez FJ. Características de los casos de dislipidemias mixtas en un estudio de población: resultados de la Encuesta Nacional de Enfermedades crónicas. Salud Publica Mex 2002; 44(6):546-553.

  6. Fanghanel SG, Sánchez RL, Arellano MS. Prevalencia de factores de riesgo de enfermedad coronaria en trabajadores del Hospital General de México. Salud Publica Mex 1997; 39(5):427-432.

  7. Pedersen TR, Olsson AG, Faergerman O. Lipoprotein changes and reduction in the incidences of major coronary heart diseases events in te 4S study . Circulation 1998; 97: 1453-1460.

  8. Illingworth D. Tratamiento de la hipercolesterolemia en Clinicas médicas de Norteamérica. Mc Graw-Hill. México, vol 1/2000.

  9. Rodríguez MM, Guerrero RF. Niveles séricos de colesterol y su relación con cardiopatía isquemica, en pacientes con diabetes mellitus no insulino dependiente. Salud Publica Mex 1997; 39(5): 420-426.

  10. Durante E. Alteración en el metabolismo de los lípidos. En: Medicina Familiar y Práctica ambulatoria. Buenos Aires, Argentina. Panamericana. 2001: 689-697.

  11. Guzmán L, Cuneo C, Bendersky M y col. Prevención de la Enfermedad Cardiovascular Aterosclerótica. Recomendaciones Prácticas. Resumen de las normativas del primer grupo de Consenso en Prevención Cardiovascular htt://www.fac.org.ar/faces/publica/revistas/99v28n3/prevenci/htm.

  12. Nasiff HA, Muñiz EG. Lipicid: software para la detección, evaluación y tratamiento de las dislípidemias. Rev. Cubana Invest Biomed 1999; 18(2):86-90.

  13. Norma Oficial Mexicana 037. http://www.salud.gob.mx/unidades/cdi/nom/037ssa202.html




2020     |     www.medigraphic.com